Patents by Inventor Raghavan Rajagopalan
Raghavan Rajagopalan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11727897Abstract: Methods, systems and apparatuses may provide for technology that detects an immediate flip request associated with a current frame of a video signal and generates a modified frame in response to the immediate flip request, wherein the modified frame includes a plurality of scanlines containing transition content associated with the current frame and the successive frame. The technology may also send the modified frame to the display.Type: GrantFiled: July 29, 2019Date of Patent: August 15, 2023Assignee: Intel CorporationInventors: Gary Smith, Geethacharan Rajagopalan, Gaurav Sutaria, Raghavan Rajagopalan
-
Publication number: 20230173111Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.Type: ApplicationFiled: January 31, 2023Publication date: June 8, 2023Inventors: Martin P. Debreczeny, Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers
-
Publication number: 20230158175Abstract: A method for determining a glomerular filtration rate (GFR) in a patient includes administering to said patient a compound of Formula I and transdermally measuring spectral energy emitted by the compound of Formula I over a measurement time window. The spectral energy is emitted by the compound of Formula I in response to electromagnetic radiation delivered to the compound of Formula I. The method also includes determining the GFR in said patient based on the measured spectral energy emitted by the compound of Formula I over the measurement time window by fitting an exponential function to the spectral energy as a function of time or a linear function to the log of the spectral energy as a function of time to calculate a rate constant associated with renal clearance over the measurement time window and directly related to the GFR normalized to a body size metric of the patient.Type: ApplicationFiled: January 25, 2023Publication date: May 25, 2023Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers, Martin P. Debreczeny
-
Patent number: 11602570Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.Type: GrantFiled: October 26, 2018Date of Patent: March 14, 2023Assignee: MediBeacon Inc.Inventors: Martin P. Debreczeny, Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers
-
Patent number: 11590244Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.Type: GrantFiled: October 26, 2018Date of Patent: February 28, 2023Assignee: MediBeacon Inc.Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers, Martin P. Debreczeny
-
Publication number: 20220370615Abstract: The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine.Type: ApplicationFiled: May 4, 2021Publication date: November 24, 2022Applicant: Satara PharmaceuticalsInventor: Raghavan Rajagopalan
-
Patent number: 11351274Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.Type: GrantFiled: February 28, 2019Date of Patent: June 7, 2022Assignee: MediBeacon Inc.Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro
-
Publication number: 20220127237Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 formulas I and II may be characterized as electron withdrawing groups, white Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.Type: ApplicationFiled: January 3, 2022Publication date: April 28, 2022Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Dennis A. Moore
-
Patent number: 11185597Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.Type: GrantFiled: February 28, 2019Date of Patent: November 30, 2021Assignee: MediBeacon, Inc.Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro
-
Patent number: 10967096Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.Type: GrantFiled: February 28, 2019Date of Patent: April 6, 2021Assignee: MediBeacon Inc.Inventors: Bob O. Basore, William L. Neumann, Richard B. Dorshow, Raghavan Rajagopalan
-
Patent number: 10960104Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.Type: GrantFiled: February 28, 2019Date of Patent: March 30, 2021Assignee: MediBeacon Inc.Inventors: Bob O. Basore, William L. Neumann, Richard B. Dorshow, Raghavan Rajagopalan
-
Patent number: 10917700Abstract: Example implementations involve systems and methods for determining bandwidth savings from a rate-limiting process. A network optimization node can determine a first reference characteristic of a first portion of adaptive bit rate (ABR) media data transmitted from a first content provider to a first user equipment while rate-limiting is disabled and store in an estimation module database associated with the network optimization node, the first reference characteristic in association with the first content provider. The node can determine a first rate-limited characteristic of a second portion of the ABR media data transmitted from the first content provider to at least one of the first user equipment and a second user equipment while rate-limiting is enabled and calculate a first bandwidth savings for the first content provider associated with rate-limiting being enabled based on a difference between the first reference characteristic and the first rate-limited characteristic.Type: GrantFiled: February 1, 2019Date of Patent: February 9, 2021Assignee: Microsoft Technology Licensing, LLCInventors: Piotr Galecki, Raghavan Rajagopalan
-
Publication number: 20210035534Abstract: Methods, systems and apparatuses may provide for technology that detects an immediate flip request associated with a current frame of a video signal and generates a modified frame in response to the immediate flip request, wherein the modified frame includes a plurality of scanlines containing transition content associated with the current frame and the successive frame. The technology may also send the modified frame to the display.Type: ApplicationFiled: July 29, 2019Publication date: February 4, 2021Inventors: Gary Smith, Geethacharan Rajagopalan, Gaurav Sutaria, Raghavan Rajagopalan
-
Patent number: 10881759Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.Type: GrantFiled: July 29, 2016Date of Patent: January 5, 2021Assignee: MediBeacon Inc.Inventors: Bob O. Basore, William L. Neumann, Richard B. Dorshow, Raghavan Rajagopalan
-
Patent number: 10695445Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.Type: GrantFiled: September 27, 2018Date of Patent: June 30, 2020Assignee: MediBeacon Inc.Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro
-
Patent number: 10617687Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.Type: GrantFiled: June 10, 2016Date of Patent: April 14, 2020Assignee: MediBeacon Inc.Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Dennis A. Moore
-
Publication number: 20190246182Abstract: Example implementations involve systems and methods for determining bandwidth savings from a rate-limiting process. A network optimization node can determine a first reference characteristic of a first portion of adaptive bit rate (ABR) media data transmitted from a first content provider to a first user equipment while rate-limiting is disabled and store in an estimation module database associated with the network optimization node, the first reference characteristic in association with the first content provider. The node can determine a first rate-limited characteristic of a second portion of the ABR media data transmitted from the first content provider to at least one of the first user equipment and a second user equipment while rate-limiting is enabled and calculate a first bandwidth savings for the first content provider associated with rate-limiting being enabled based on a difference between the first reference characteristic and the first rate-limited characteristic.Type: ApplicationFiled: February 1, 2019Publication date: August 8, 2019Inventors: Piotr GALECKI, Raghavan RAJAGOPALAN
-
Pyrazine derivatives with extended conjugation and methods of using the same in optical applications
Patent number: 10370362Abstract: The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.Type: GrantFiled: December 8, 2015Date of Patent: August 6, 2019Assignee: MediBeacon Inc.Inventors: William L. Neumann, Raghavan Rajagopalan, Richard B. Dorshow -
Publication number: 20190192727Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.Type: ApplicationFiled: February 28, 2019Publication date: June 27, 2019Inventors: Bob O. Basore, William L. Neumann, Richard B. Dorshow, Raghavan Rajagopalan
-
Publication number: 20190192696Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.Type: ApplicationFiled: February 28, 2019Publication date: June 27, 2019Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro